JP2019505567A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505567A5
JP2019505567A5 JP2018549369A JP2018549369A JP2019505567A5 JP 2019505567 A5 JP2019505567 A5 JP 2019505567A5 JP 2018549369 A JP2018549369 A JP 2018549369A JP 2018549369 A JP2018549369 A JP 2018549369A JP 2019505567 A5 JP2019505567 A5 JP 2019505567A5
Authority
JP
Japan
Prior art keywords
construct
hpv
sequence
coding sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549369A
Other languages
English (en)
Japanese (ja)
Other versions
JP7110108B2 (ja
JPWO2017096432A5 (enExample
JP2019505567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/051214 external-priority patent/WO2017096432A1/en
Publication of JP2019505567A publication Critical patent/JP2019505567A/ja
Publication of JP2019505567A5 publication Critical patent/JP2019505567A5/ja
Publication of JPWO2017096432A5 publication Critical patent/JPWO2017096432A5/ja
Application granted granted Critical
Publication of JP7110108B2 publication Critical patent/JP7110108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549369A 2015-12-09 2016-12-09 治療用免疫調節組成物 Active JP7110108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905099A AU2015905099A0 (en) 2015-12-09 Immunomodulating composition for treatment
AU2015905099 2015-12-09
PCT/AU2016/051214 WO2017096432A1 (en) 2015-12-09 2016-12-09 Immunomodulating composition for treatment

Publications (4)

Publication Number Publication Date
JP2019505567A JP2019505567A (ja) 2019-02-28
JP2019505567A5 true JP2019505567A5 (enExample) 2020-01-23
JPWO2017096432A5 JPWO2017096432A5 (enExample) 2022-05-11
JP7110108B2 JP7110108B2 (ja) 2022-08-01

Family

ID=59012459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549369A Active JP7110108B2 (ja) 2015-12-09 2016-12-09 治療用免疫調節組成物

Country Status (8)

Country Link
US (1) US10596248B2 (enExample)
EP (1) EP3386593A4 (enExample)
JP (1) JP7110108B2 (enExample)
KR (1) KR102895580B1 (enExample)
CN (1) CN108601951B (enExample)
AU (1) AU2016367712B2 (enExample)
CA (1) CA3006779A1 (enExample)
WO (1) WO2017096432A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7581048B2 (ja) 2018-03-06 2024-11-12 プレシゲン,インコーポレイテッド ヒトパピローマウイルスワクチンおよびその使用
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
AU2019401282A1 (en) * 2018-12-20 2021-07-15 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
WO2022235976A1 (en) * 2021-05-06 2022-11-10 Systems Oncology, Llc Multitargeting rna compositions
CN114134165B (zh) * 2022-01-27 2022-04-29 北京循生生物医学研究有限公司 一种新型hpv治疗性核酸疫苗
WO2024131833A1 (en) * 2022-12-21 2024-06-27 Abogen Biosciences (Shanghai) Co., Ltd. Mrna-based hpv+ cancer vaccines, and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US417671A (en) 1889-12-17 Henry esbach
US606909A (en) 1898-07-05 barnard
US4184917A (en) 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
US4321365A (en) 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4293652A (en) 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4351901A (en) 1980-03-24 1982-09-28 Cetus Corporation Method for single nucleotide alteration
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
EP0500799B1 (en) 1989-11-16 1998-01-14 Duke University Particle mediated transformation of animal skin tissue cells
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
CA2092195C (en) 1990-09-21 2000-04-18 Douglas J. Jolly Retroviral packaging cell line
ATE188740T1 (de) 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
DE69420033T2 (de) 1993-04-06 1999-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Bethesda Gibbon leukemia virus retrovirale vektoren
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US6140087A (en) 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US6120764A (en) 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU7353494A (en) 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
JP3221683B2 (ja) 1994-01-21 2001-10-22 パウダージェクト ヴァクシンズ, インコーポレイテッド ガス駆動型遺伝子搬入装置
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
DE69535125T2 (de) 1994-04-29 2007-08-30 Pharmacia & Upjohn Co. Llc, Kalamazoo Impfstoff gegen felines immunodefizienz-virus
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えdnaウイルスおよびその製造方法
GB9506782D0 (en) 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2247091A1 (en) 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2288328A1 (en) 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO2000000600A2 (en) 1997-09-22 2000-01-06 Chang Lung Ji Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US7048929B1 (en) 1997-11-10 2006-05-23 Dana-Farber Cancer Institute, Inc. Stabilized primate lentivirus envelope glycoproteins
WO1999030742A1 (en) 1997-12-12 1999-06-24 Luigi Naldini Therapeutic use of lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999051754A1 (en) 1998-04-02 1999-10-14 Dana-Farber Cancer Institute, Inc. Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof
JP4800485B2 (ja) 1999-03-26 2011-10-26 バイカル インコーポレイテッド ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法
WO2000061772A2 (en) 1999-04-14 2000-10-19 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2000066759A1 (en) 1999-04-29 2000-11-09 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1214097B3 (en) * 1999-09-16 2011-07-20 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU2001249380A1 (en) 2000-03-22 2001-11-07 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
ATE499948T1 (de) 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
ATE354662T1 (de) 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド キメラアルファウイルスレプリコン粒子
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
ES2443216T3 (es) 2006-04-19 2014-02-18 Postech Academy-Industry Foundation Proteínas de fusión que comprenden polipéptidos de VPH y péptidos de inmunopotenciación de tratamiento y prevención del cáncer cervicouterino
EP2215231A4 (en) * 2007-10-15 2010-12-01 Univ Queensland EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
US9050287B2 (en) * 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
PL2604629T3 (pl) 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
KR101206514B1 (ko) 2012-08-10 2012-11-30 서석윤 완충성이 우수한 목발
CN103772508B (zh) 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
JP6724853B2 (ja) 2017-04-24 2020-07-15 アイシン精機株式会社 駐車支援装置

Similar Documents

Publication Publication Date Title
JP2019505567A5 (enExample)
JP2015514132A5 (enExample)
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
JP2016539946A5 (enExample)
JP2015501840A5 (enExample)
JP2014000092A5 (enExample)
JP2010166916A5 (enExample)
JP2012515557A5 (enExample)
JP2018510622A5 (enExample)
JP2012115277A5 (enExample)
WO2015024668A3 (en) Respiratory syncytial virus (rsv) vaccine
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2014500724A5 (enExample)
JP2009544333A5 (enExample)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2013523718A5 (enExample)
JP2015521206A5 (enExample)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2019534884A5 (enExample)
JP2019534709A5 (enExample)
WO2015107363A3 (en) Mycobacterial antigen composition
JP2014519817A5 (enExample)
JP2016520534A5 (enExample)
HRP20241627T1 (hr) Pneumolizinski mutanti i postupci za njihovu uporabu
JP2017522326A5 (enExample)